RxDoctor Payments Data

Stuart Cohen, MD

Infectious Disease · Sacramento, CANPI 1043290455

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,800 of the $11,872 with a category attached, or 74.1%. Modernatx, Inc. accounts for 65.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $9,413 and has fallen 86.9% since, to $1,236 in 2024.

$11,872in general payments, 2019–2025

Across 10 payments — averaging $1187.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$8K
  • Pfizer$3K
  • Shionogi Inc$1K
  • Johnson & Johnson$28
  • Merck$24
$2,486,998in research payments, 2019–2025

Across 375 payments — averaging $6631.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$929K
  • Regeneron$514K
  • Merck$299K
  • Pfizer$204K
  • Eiger Biopharmaceuticals, Inc.$125K
  • AstraZeneca$107K
  • plus $309K from 8 others

What the payments were for

  • Consulting fees$2,65022%
  • Speaking & faculty fees$8,80074%
  • Food & beverage$3703%
  • Education$520%

General payments by program year

20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.2$7,800
Pfizer4$2,850
Shionogi Inc1$1,170
Johnson & Johnson1$28
Merck2$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,872 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$38,398
Medicare patients
205
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala141$560,242
TriumeqAbacavir/Dolutegravir/Lamivudi116$407,223
GenvoyaElviteg/Cob/Emtri/Tenof Alafen53$237,978
NuzyraOmadacycline Tosylate14$191,914
OdefseyEmtricitab/Rilpiviri/Tenof Ala54$183,929
DescovyEmtricitabine/Tenofov Alafenam87$174,931
JulucaDolutegravir/Rilpivirine44$169,779
CabenuvaCabotegravir/Rilpivirine13$75,880
PrezcobixDarunavir/Cobicistat34$73,326
Isentress HdRaltegravir Potassium39$64,501
DovatoDolutegravir Sodium/Lamivudine22$62,422
TivicayDolutegravir Sodium28$57,430
PifeltroDoravirine32$54,399
CresembaIsavuconazonium Sulfate12$44,851
Posaconazole36$42,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckIsentress Hd, Pifeltro$24$118,90071 claims
Johnson & JohnsonPrezcobix$28$73,32634 claims
PfizerEliquis$2,850$6,43111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 856 infectious disease providers in California.

Other infectious disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →